Skip to main content
Erschienen in: American Journal of Clinical Dermatology 1/2022

03.11.2021 | Review Article

Identifying and Treating Ocular Manifestations in Psoriasis

verfasst von: Mahsaw Motlagh, Christopher Fortenbach, Howard I. Maibach, Bobeck S. Modjtahedi

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Psoriasis is a chronic immune-mediated inflammatory skin condition that commonly presents with red, thickened, and scaling plaques. Given the prominent cutaneous manifestations of psoriasis, more subtle ophthalmic findings of the disease may initially go undetected, with the potential for significant ocular morbidity. Associated ocular disease can involve nearly any structure of the eye, with the eyelids most commonly being affected, resulting in relatively common signs and symptoms of ocular surface discomfort. The presence of intraocular inflammation (i.e., uveitis) or retinal involvement carry a heightened risk of vision loss, and are often more difficult to diagnose outside of the ophthalmology clinic. Early detection and treatment of ocular disease can limit morbidity and are critical to the management of these patients, which requires coordination of care between dermatologists and ophthalmologists. The objective of this article was to review the most common ocular conditions that affect psoriatic patients, when to consider referral to an ophthalmologist, and to summarize the adverse ocular effects of current psoriasis treatments.
Literatur
1.
Zurück zum Zitat Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–60.PubMed Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–60.PubMed
2.
Zurück zum Zitat Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–6.PubMed Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–6.PubMed
3.
Zurück zum Zitat Enamandram M, Kimball AB. Psoriasis epidemiology: the interplay of genes and the environment. J Invest Dermatol. 2013;133(2):287–9.PubMed Enamandram M, Kimball AB. Psoriasis epidemiology: the interplay of genes and the environment. J Invest Dermatol. 2013;133(2):287–9.PubMed
4.
Zurück zum Zitat Parisi R, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–85.PubMed Parisi R, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–85.PubMed
5.
Zurück zum Zitat Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–12.PubMed Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–12.PubMed
6.
Zurück zum Zitat Burshtein J, Strunk A, Garg A. Incidence of psoriasis among adults in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. 2021;84(4):1023–9.PubMed Burshtein J, Strunk A, Garg A. Incidence of psoriasis among adults in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. 2021;84(4):1023–9.PubMed
7.
Zurück zum Zitat Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–94.PubMed Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–94.PubMed
8.
Zurück zum Zitat Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–71.PubMed Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–71.PubMed
9.
Zurück zum Zitat Chandran NS, et al. Psoriasis and the eye: prevalence of eye disease in Singaporean Asian patients with psoriasis. J Dermatol. 2007;34(12):805–10.PubMed Chandran NS, et al. Psoriasis and the eye: prevalence of eye disease in Singaporean Asian patients with psoriasis. J Dermatol. 2007;34(12):805–10.PubMed
10.
Zurück zum Zitat Cruz N, et al. Ocular manifestations of psoriasis. Arq Bras Oftalmol. 2018;81(3):219–25.PubMed Cruz N, et al. Ocular manifestations of psoriasis. Arq Bras Oftalmol. 2018;81(3):219–25.PubMed
11.
Zurück zum Zitat Abbagani S, Kamath YS, Nayak S. A study on ocular morbidity among patients with psoriasis visiting a Tertiary Care Hospital in Karnataka, Southern India. Ocul Immunol Inflamm. 2019;27(4):531–4.PubMed Abbagani S, Kamath YS, Nayak S. A study on ocular morbidity among patients with psoriasis visiting a Tertiary Care Hospital in Karnataka, Southern India. Ocul Immunol Inflamm. 2019;27(4):531–4.PubMed
12.
Zurück zum Zitat Rehal B, et al. Ocular psoriasis. J Am Acad Dermatol. 2011;65(6):1202–12.PubMed Rehal B, et al. Ocular psoriasis. J Am Acad Dermatol. 2011;65(6):1202–12.PubMed
13.
Zurück zum Zitat Webster GF, Durrani K, Suchecki J. Ocular rosacea, psoriasis, and lichen planus. Clin Dermatol. 2016;34(2):146–50.PubMed Webster GF, Durrani K, Suchecki J. Ocular rosacea, psoriasis, and lichen planus. Clin Dermatol. 2016;34(2):146–50.PubMed
14.
Zurück zum Zitat Gonzalez-Andrades M, et al. Sterile corneal infiltrates secondary to psoriasis exacerbations: topical tacrolimus as an alternative treatment option. Eye Contact Lens. 2017;43(1):e1–3.PubMed Gonzalez-Andrades M, et al. Sterile corneal infiltrates secondary to psoriasis exacerbations: topical tacrolimus as an alternative treatment option. Eye Contact Lens. 2017;43(1):e1–3.PubMed
15.
Zurück zum Zitat Donshik PC, Hoss DM, Ehlers WH. Inflammatory and papulosquamous disorders of the skin and eye. Dermatol Clin. 1992;10(3):533–47.PubMed Donshik PC, Hoss DM, Ehlers WH. Inflammatory and papulosquamous disorders of the skin and eye. Dermatol Clin. 1992;10(3):533–47.PubMed
17.
Zurück zum Zitat Bernhard JD. Is eyelid involvement a sign of severe psoriasis? Dermatologica. 1987;174(3):151.PubMed Bernhard JD. Is eyelid involvement a sign of severe psoriasis? Dermatologica. 1987;174(3):151.PubMed
18.
Zurück zum Zitat Ajitsaria R, et al. Psoriasis, psoriatic arthropathy and relapsing orbital myositis. Clin Exp Dermatol. 2001;26(3):274–5.PubMed Ajitsaria R, et al. Psoriasis, psoriatic arthropathy and relapsing orbital myositis. Clin Exp Dermatol. 2001;26(3):274–5.PubMed
19.
Zurück zum Zitat Ssi-Yan-Kai I, Pearson A. Orbital myositis and psoriatic arthritis. Can J Ophthalmol. 2012;47(6):e42–3.PubMed Ssi-Yan-Kai I, Pearson A. Orbital myositis and psoriatic arthritis. Can J Ophthalmol. 2012;47(6):e42–3.PubMed
20.
Zurück zum Zitat Kilic B, et al. Ocular findings in patients with psoriasis. Int J Dermatol. 2013;52(5):554–9.PubMed Kilic B, et al. Ocular findings in patients with psoriasis. Int J Dermatol. 2013;52(5):554–9.PubMed
21.
Zurück zum Zitat Zengin N, et al. Tear film and meibomian gland functions in psoriasis. Acta Ophthalmol Scand. 1996;74(4):358–60.PubMed Zengin N, et al. Tear film and meibomian gland functions in psoriasis. Acta Ophthalmol Scand. 1996;74(4):358–60.PubMed
22.
Zurück zum Zitat Her Y, Lim JW, Han SH. Dry eye and tear film functions in patients with psoriasis. Jpn J Ophthalmol. 2013;57(4):341–6.PubMed Her Y, Lim JW, Han SH. Dry eye and tear film functions in patients with psoriasis. Jpn J Ophthalmol. 2013;57(4):341–6.PubMed
23.
Zurück zum Zitat Aragona E, et al. Tear film and ocular surface assessment in psoriasis. Br J Ophthalmol. 2018;102(3):302–8.PubMed Aragona E, et al. Tear film and ocular surface assessment in psoriasis. Br J Ophthalmol. 2018;102(3):302–8.PubMed
24.
Zurück zum Zitat Karabulut AA, et al. Conjunctival impression cytology and tear-film changes in patients with psoriasis. Cornea. 1999;18(5):544–8.PubMed Karabulut AA, et al. Conjunctival impression cytology and tear-film changes in patients with psoriasis. Cornea. 1999;18(5):544–8.PubMed
25.
Zurück zum Zitat Demirci G, et al. Tear osmolarity and ocular surface parameters in patients with psoriasis. Arq Bras Oftalmol. 2017;80(1):1–3.PubMed Demirci G, et al. Tear osmolarity and ocular surface parameters in patients with psoriasis. Arq Bras Oftalmol. 2017;80(1):1–3.PubMed
26.
Zurück zum Zitat Huynh N, et al. Biologic response modifier therapy for psoriatic ocular inflammatory disease. Ocul Immunol Inflamm. 2008;16(3):89–93.PubMed Huynh N, et al. Biologic response modifier therapy for psoriatic ocular inflammatory disease. Ocul Immunol Inflamm. 2008;16(3):89–93.PubMed
27.
Zurück zum Zitat Amin KA, Belsito DV. The aetiology of eyelid dermatitis: a 10-year retrospective analysis. Contact Dermatitis. 2006;55(5):280–5.PubMed Amin KA, Belsito DV. The aetiology of eyelid dermatitis: a 10-year retrospective analysis. Contact Dermatitis. 2006;55(5):280–5.PubMed
28.
Zurück zum Zitat Demerdjieva Z, Mazhdrakova I, Tsankov N. Ocular changes in patients with psoriasis. Clin Dermatol. 2019;37(6):663–7.PubMed Demerdjieva Z, Mazhdrakova I, Tsankov N. Ocular changes in patients with psoriasis. Clin Dermatol. 2019;37(6):663–7.PubMed
29.
Zurück zum Zitat Catsarou-Catsari A, et al. Ophthalmological manifestations in patients with psoriasis. Acta Derm Venereol. 1984;64(6):557–9.PubMed Catsarou-Catsari A, et al. Ophthalmological manifestations in patients with psoriasis. Acta Derm Venereol. 1984;64(6):557–9.PubMed
30.
Zurück zum Zitat Vrabec F. Histologic description of a case of psoriasis with conjunctival, corneal and cutaneous localization. Ophthalmologica. 1952;124(2):105–8 (In undetermined language).PubMed Vrabec F. Histologic description of a case of psoriasis with conjunctival, corneal and cutaneous localization. Ophthalmologica. 1952;124(2):105–8 (In undetermined language).PubMed
31.
Zurück zum Zitat Amer R, Levinger N. Psoriasis-associated progressive necrotizing posterior scleritis: a 6-year follow-up. Eur J Ophthalmol. 2020;30(3):Np7–10.PubMed Amer R, Levinger N. Psoriasis-associated progressive necrotizing posterior scleritis: a 6-year follow-up. Eur J Ophthalmol. 2020;30(3):Np7–10.PubMed
32.
Zurück zum Zitat Stacy RC, et al. Posterior necrotizing scleritis presenting as sectoral chorioretinitis. Ocul Immunol Inflamm. 2015;23(5):412–5.PubMed Stacy RC, et al. Posterior necrotizing scleritis presenting as sectoral chorioretinitis. Ocul Immunol Inflamm. 2015;23(5):412–5.PubMed
33.
Zurück zum Zitat Altan-Yaycioglu R, et al. Posterior scleritis in psoriatic arthritis. Retina. 2003;23(5):717–9.PubMed Altan-Yaycioglu R, et al. Posterior scleritis in psoriatic arthritis. Retina. 2003;23(5):717–9.PubMed
34.
Zurück zum Zitat Boss JM, et al. Peripheral corneal melting syndrome in association with psoriasis: a report of two cases. Br Med J (Clin Res Ed). 1981;282(6264):609–10. Boss JM, et al. Peripheral corneal melting syndrome in association with psoriasis: a report of two cases. Br Med J (Clin Res Ed). 1981;282(6264):609–10.
35.
Zurück zum Zitat Moadel K, et al. Psoriatic corneal abscess. Am J Ophthalmol. 1995;119(6):800–1.PubMed Moadel K, et al. Psoriatic corneal abscess. Am J Ophthalmol. 1995;119(6):800–1.PubMed
36.
Zurück zum Zitat Herbert VG, et al. Ulcerative keratitis in psoriasis: a rare variant of psoriatic ocular inflammatory disease. Br J Dermatol. 2014;170(3):746–8.PubMed Herbert VG, et al. Ulcerative keratitis in psoriasis: a rare variant of psoriatic ocular inflammatory disease. Br J Dermatol. 2014;170(3):746–8.PubMed
37.
Zurück zum Zitat Filev FS, et al. Psoriasis-associated keratitis: case report. Ophthalmologe. 2014;111(12):1201–3 (In German).PubMed Filev FS, et al. Psoriasis-associated keratitis: case report. Ophthalmologe. 2014;111(12):1201–3 (In German).PubMed
38.
Zurück zum Zitat Jeng BH, Downs-Kelly E, Langston RH. Superficial hypertrophic dendritic epitheliopathy occurring before and after penetrating keratoplasty in a patient with psoriasis. Cornea. 2006;25(9):1097–9.PubMed Jeng BH, Downs-Kelly E, Langston RH. Superficial hypertrophic dendritic epitheliopathy occurring before and after penetrating keratoplasty in a patient with psoriasis. Cornea. 2006;25(9):1097–9.PubMed
39.
Zurück zum Zitat Lafond G, Roy PE, Grenier R. Lens opacities appearing during therapy with methoxsalen and long-wavelength ultraviolet radiation. Can J Ophthalmol. 1984;19(4):173–5.PubMed Lafond G, Roy PE, Grenier R. Lens opacities appearing during therapy with methoxsalen and long-wavelength ultraviolet radiation. Can J Ophthalmol. 1984;19(4):173–5.PubMed
40.
Zurück zum Zitat See JA, Weller P. Ocular complications of PUVA therapy. Australas J Dermatol. 1993;34(1):1–4.PubMed See JA, Weller P. Ocular complications of PUVA therapy. Australas J Dermatol. 1993;34(1):1–4.PubMed
41.
Zurück zum Zitat DePry J, et al. Phototherapy-related ophthalmologic disorders. Clin Dermatol. 2015;33(2):247–55.PubMed DePry J, et al. Phototherapy-related ophthalmologic disorders. Clin Dermatol. 2015;33(2):247–55.PubMed
42.
Zurück zum Zitat Malanos D, Stern RS. Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study. J Am Acad Dermatol. 2007;57(2):231–7.PubMed Malanos D, Stern RS. Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study. J Am Acad Dermatol. 2007;57(2):231–7.PubMed
43.
Zurück zum Zitat Woo TY, et al. Lenticular psoralen photoproducts and cataracts of a PUVA-treated psoriatic patient. Arch Dermatol. 1985;121(10):1307–8.PubMed Woo TY, et al. Lenticular psoralen photoproducts and cataracts of a PUVA-treated psoriatic patient. Arch Dermatol. 1985;121(10):1307–8.PubMed
44.
Zurück zum Zitat Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–16.PubMed Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–16.PubMed
46.
Zurück zum Zitat Durrani K, Foster CS. Psoriatic uveitis: a distinct clinical entity? Am J Ophthalmol. 2005;139(1):106–11.PubMed Durrani K, Foster CS. Psoriatic uveitis: a distinct clinical entity? Am J Ophthalmol. 2005;139(1):106–11.PubMed
49.
Zurück zum Zitat Chi CC, et al. Risk of uveitis among people with psoriasis: a Nationwide Cohort Study. JAMA Ophthalmol. 2017;135(5):415–22.PubMedPubMedCentral Chi CC, et al. Risk of uveitis among people with psoriasis: a Nationwide Cohort Study. JAMA Ophthalmol. 2017;135(5):415–22.PubMedPubMedCentral
50.
Zurück zum Zitat Abbouda A, et al. Psoriasis and psoriatic arthritis-related uveitis: different ophthalmological manifestations and ocular inflammation features. Semin Ophthalmol. 2017;32(6):715–20.PubMed Abbouda A, et al. Psoriasis and psoriatic arthritis-related uveitis: different ophthalmological manifestations and ocular inflammation features. Semin Ophthalmol. 2017;32(6):715–20.PubMed
51.
Zurück zum Zitat Lam M, et al. The incidence and prevalence of uveitis in psoriasis: a systematic review and meta-analysis. J Cutan Med Surg. 2020;24(6):601–7.PubMed Lam M, et al. The incidence and prevalence of uveitis in psoriasis: a systematic review and meta-analysis. J Cutan Med Surg. 2020;24(6):601–7.PubMed
52.
Zurück zum Zitat Egeberg A, et al. Association of psoriatic disease with uveitis: a Danish Nationwide Cohort Study. JAMA Dermatol. 2015;151(11):1200–5.PubMed Egeberg A, et al. Association of psoriatic disease with uveitis: a Danish Nationwide Cohort Study. JAMA Dermatol. 2015;151(11):1200–5.PubMed
53.
Zurück zum Zitat Okamoto F, et al. Factors associated with increased aqueous flare in psoriasis. Jpn J Ophthalmol. 2001;45(2):172–6.PubMed Okamoto F, et al. Factors associated with increased aqueous flare in psoriasis. Jpn J Ophthalmol. 2001;45(2):172–6.PubMed
54.
Zurück zum Zitat Oon HH, et al. Acute unilateral red eye in a patient with psoriasis. Clin Exp Dermatol. 2019;44(8):924–6.PubMed Oon HH, et al. Acute unilateral red eye in a patient with psoriasis. Clin Exp Dermatol. 2019;44(8):924–6.PubMed
56.
Zurück zum Zitat Abu-Yaghi NE, et al. White dot syndromes: a 20-year study of incidence, clinical features, and outcomes. Ocul Immunol Inflamm. 2011;19(6):426–30.PubMedPubMedCentral Abu-Yaghi NE, et al. White dot syndromes: a 20-year study of incidence, clinical features, and outcomes. Ocul Immunol Inflamm. 2011;19(6):426–30.PubMedPubMedCentral
57.
Zurück zum Zitat Hesse S, et al. Psoriasis and birdshot chorioretinopathy: response to aromatic retinoids. Dermatology. 1993;187(2):137–9.PubMed Hesse S, et al. Psoriasis and birdshot chorioretinopathy: response to aromatic retinoids. Dermatology. 1993;187(2):137–9.PubMed
59.
Zurück zum Zitat Dai YX, et al. Risk of retinal diseases in patients with psoriasis: a population-based cohort study in Taiwan. J Dermatol. 2021;48(10):1550–6.PubMed Dai YX, et al. Risk of retinal diseases in patients with psoriasis: a population-based cohort study in Taiwan. J Dermatol. 2021;48(10):1550–6.PubMed
60.
Zurück zum Zitat Castellino N, et al. Retinal vascular assessment in psoriasis: a multicenter study. Front Neurosci. 2021;15:30. Castellino N, et al. Retinal vascular assessment in psoriasis: a multicenter study. Front Neurosci. 2021;15:30.
62.
Zurück zum Zitat Aksoy M, Toptan M, An I. Retinal nerve fiber layer thickness and choroidal thickness: an evaluation in psoriasis patients. Int J Clin Pract. 2021;75(4): e13904.PubMed Aksoy M, Toptan M, An I. Retinal nerve fiber layer thickness and choroidal thickness: an evaluation in psoriasis patients. Int J Clin Pract. 2021;75(4): e13904.PubMed
63.
Zurück zum Zitat Ersan I, et al. Evaluation of macular ganglion cell-inner plexiform layer and choroid in psoriasis patients using enhanced depth imaging spectral domain optical coherence tomography. Ocul Immunol Inflamm. 2017;25(4):520–4.PubMed Ersan I, et al. Evaluation of macular ganglion cell-inner plexiform layer and choroid in psoriasis patients using enhanced depth imaging spectral domain optical coherence tomography. Ocul Immunol Inflamm. 2017;25(4):520–4.PubMed
64.
Zurück zum Zitat Kılıç R, et al. Choroidal thickness in psoriasis. Int Ophthalmol. 2017;37(1):173–7.PubMed Kılıç R, et al. Choroidal thickness in psoriasis. Int Ophthalmol. 2017;37(1):173–7.PubMed
65.
Zurück zum Zitat Kao LT, et al. Association between psoriasis and neovascular age-related macular degeneration: a population-based study. J Am Acad Dermatol. 2015;72(6):1090–2.PubMed Kao LT, et al. Association between psoriasis and neovascular age-related macular degeneration: a population-based study. J Am Acad Dermatol. 2015;72(6):1090–2.PubMed
66.
Zurück zum Zitat Yen YC, et al. Risk of retinal vein occlusion in patients with psoriasis: a population-based cohort study. Retina. 2015;35(9):1786–94.PubMed Yen YC, et al. Risk of retinal vein occlusion in patients with psoriasis: a population-based cohort study. Retina. 2015;35(9):1786–94.PubMed
67.
Zurück zum Zitat Ghalamkarpour F, et al. Ocular findings in patients with psoriasis: is it related to the side effects of treatment or to psoriasis itself? A case-control study. J Dermatolog Treat. 2020;31(1):27–32.PubMed Ghalamkarpour F, et al. Ocular findings in patients with psoriasis: is it related to the side effects of treatment or to psoriasis itself? A case-control study. J Dermatolog Treat. 2020;31(1):27–32.PubMed
68.
Zurück zum Zitat Nicolela Susanna F, Pavesio C. A review of ocular adverse events of biological anti-TNF drugs. J Ophthalmic Inflamm Infect. 2020;10(1):11.PubMedPubMedCentral Nicolela Susanna F, Pavesio C. A review of ocular adverse events of biological anti-TNF drugs. J Ophthalmic Inflamm Infect. 2020;10(1):11.PubMedPubMedCentral
69.
Zurück zum Zitat Cram DL. Corneal melting in psoriasis. J Am Acad Dermatol. 1981;5(5):617.PubMed Cram DL. Corneal melting in psoriasis. J Am Acad Dermatol. 1981;5(5):617.PubMed
70.
Zurück zum Zitat Fraunfelder FT, Fraunfelder FW. Possible association between apremilast therapy and increased tearing. Ophthalmic Plast Reconstr Surg. 2021;37(3 Suppl):S31–2.PubMed Fraunfelder FT, Fraunfelder FW. Possible association between apremilast therapy and increased tearing. Ophthalmic Plast Reconstr Surg. 2021;37(3 Suppl):S31–2.PubMed
71.
Zurück zum Zitat Fraunfelder FW, Fraunfelder FT. Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology. 2004;111(7):1275–9.PubMed Fraunfelder FW, Fraunfelder FT. Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology. 2004;111(7):1275–9.PubMed
72.
Zurück zum Zitat Fraunfelder FT, Fraunfelder FW, Edwards R. Ocular side effects possibly associated with isotretinoin usage. Am J Ophthalmol. 2001;132(3):299–305.PubMed Fraunfelder FT, Fraunfelder FW, Edwards R. Ocular side effects possibly associated with isotretinoin usage. Am J Ophthalmol. 2001;132(3):299–305.PubMed
73.
Zurück zum Zitat Lebowitz MA, Berson DS. Ocular effects of oral retinoids. J Am Acad Dermatol. 1988;19(1 Pt 2):209–11.PubMed Lebowitz MA, Berson DS. Ocular effects of oral retinoids. J Am Acad Dermatol. 1988;19(1 Pt 2):209–11.PubMed
74.
Zurück zum Zitat Lois N, White M. Acitretin-associated maculopathy. Arch Ophthalmol. 2004;122(6):928–30.PubMed Lois N, White M. Acitretin-associated maculopathy. Arch Ophthalmol. 2004;122(6):928–30.PubMed
75.
Zurück zum Zitat LaMattina KC, Goldstein DA. Adalimumab for the treatment of uveitis. Expert Rev Clin Immunol. 2017;13(3):181–8.PubMed LaMattina KC, Goldstein DA. Adalimumab for the treatment of uveitis. Expert Rev Clin Immunol. 2017;13(3):181–8.PubMed
76.
Zurück zum Zitat Cunningham ET Jr, et al. Drug-induced inflammation in patients on TNFα inhibitors. Ocul Immunol Inflamm. 2012;20(1):2–5.PubMed Cunningham ET Jr, et al. Drug-induced inflammation in patients on TNFα inhibitors. Ocul Immunol Inflamm. 2012;20(1):2–5.PubMed
77.
Zurück zum Zitat Damento G, et al. Clinical and histologic findings in patients with uveal melanomas after taking tumor necrosis factor-α inhibitors. Mayo Clin Proc. 2014;89(11):1481–6.PubMed Damento G, et al. Clinical and histologic findings in patients with uveal melanomas after taking tumor necrosis factor-α inhibitors. Mayo Clin Proc. 2014;89(11):1481–6.PubMed
78.
Zurück zum Zitat Drury J, Hickman SJ. Internuclear ophthalmoplegia associated with anti-TNFα medication. Strabismus. 2015;23(1):30–2.PubMed Drury J, Hickman SJ. Internuclear ophthalmoplegia associated with anti-TNFα medication. Strabismus. 2015;23(1):30–2.PubMed
79.
Zurück zum Zitat Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? Observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res. 2010;35(8):751–6.PubMed Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? Observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res. 2010;35(8):751–6.PubMed
80.
Zurück zum Zitat Leal I, et al. Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis—a systematic review. Acta Ophthalmol. 2018;96(6):e665–75.PubMed Leal I, et al. Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis—a systematic review. Acta Ophthalmol. 2018;96(6):e665–75.PubMed
81.
Zurück zum Zitat Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A Registry-Based Study. Arthritis Rheum. 2007;56(10):3248–52.PubMed Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A Registry-Based Study. Arthritis Rheum. 2007;56(10):3248–52.PubMed
82.
Zurück zum Zitat Montero JA, et al. Endogenous endophthalmitis by Propionibacterium acnes associated with leflunomide and adalimumab therapy. Eur J Ophthalmol. 2006;16(2):343–5.PubMed Montero JA, et al. Endogenous endophthalmitis by Propionibacterium acnes associated with leflunomide and adalimumab therapy. Eur J Ophthalmol. 2006;16(2):343–5.PubMed
83.
Zurück zum Zitat Seror R, et al. Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey. Rheumatology (Oxford). 2013;52(5):868–74. Seror R, et al. Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey. Rheumatology (Oxford). 2013;52(5):868–74.
84.
Zurück zum Zitat Tsilimbaris M, et al. Evaluation of potential retinal toxicity of adalimumab (Humira). Graefes Arch Clin Exp Ophthalmol. 2009;247(8):1119–25.PubMed Tsilimbaris M, et al. Evaluation of potential retinal toxicity of adalimumab (Humira). Graefes Arch Clin Exp Ophthalmol. 2009;247(8):1119–25.PubMed
85.
Zurück zum Zitat Wendling D, et al. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Curr Med Res Opin. 2014;30(12):2515–21.PubMed Wendling D, et al. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Curr Med Res Opin. 2014;30(12):2515–21.PubMed
86.
Zurück zum Zitat Wendling D, et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. 2011;41(3):503–10.PubMed Wendling D, et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. 2011;41(3):503–10.PubMed
87.
Zurück zum Zitat Winthrop KL, et al. Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol. 2013;155(1):183-189.e1.PubMed Winthrop KL, et al. Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol. 2013;155(1):183-189.e1.PubMed
88.
Zurück zum Zitat Arriola-Villalobos P, et al. Bilateral Candida chorioretinitis following etanercept treatment for hidradenitis suppurativa. Eye (Lond). 2008;22(4):599–600. Arriola-Villalobos P, et al. Bilateral Candida chorioretinitis following etanercept treatment for hidradenitis suppurativa. Eye (Lond). 2008;22(4):599–600.
89.
Zurück zum Zitat Brito-Zerón P, Perez-Alvarez R, Ramos-Casals M. Etanercept and uveitis: friends or foes? Curr Med Res Opin. 2015;31(2):251–2.PubMed Brito-Zerón P, Perez-Alvarez R, Ramos-Casals M. Etanercept and uveitis: friends or foes? Curr Med Res Opin. 2015;31(2):251–2.PubMed
90.
Zurück zum Zitat Gaujoux-Viala C, et al. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol. 2012;39(2):233–9.PubMed Gaujoux-Viala C, et al. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol. 2012;39(2):233–9.PubMed
91.
Zurück zum Zitat Kowalski T, Mack HG. Ocular complications of tumour necrosis factor alpha inhibitors. Clin Exp Optom. 2020;103(2):148–54.PubMed Kowalski T, Mack HG. Ocular complications of tumour necrosis factor alpha inhibitors. Clin Exp Optom. 2020;103(2):148–54.PubMed
92.
Zurück zum Zitat Lezcano Carduz VP, Mingo Botín D, Durán Poveda SP. Squamous cell neoplasm of the ocular surface in a patient with psoriasis treated with tumor necrosis factor-alpha inhibitors. Cornea. 2015;34(7):833–4.PubMed Lezcano Carduz VP, Mingo Botín D, Durán Poveda SP. Squamous cell neoplasm of the ocular surface in a patient with psoriasis treated with tumor necrosis factor-alpha inhibitors. Cornea. 2015;34(7):833–4.PubMed
93.
Zurück zum Zitat Matet A, et al. Systemic adalimumab induces peripheral corneal infiltrates: a case report. BMC Ophthalmol. 2015;15:57.PubMedPubMedCentral Matet A, et al. Systemic adalimumab induces peripheral corneal infiltrates: a case report. BMC Ophthalmol. 2015;15:57.PubMedPubMedCentral
94.
Zurück zum Zitat Noguera-Pons R, et al. Optic neuritis with concurrent etanercept and isoniazid therapy. Ann Pharmacother. 2005;39(12):2131–5.PubMed Noguera-Pons R, et al. Optic neuritis with concurrent etanercept and isoniazid therapy. Ann Pharmacother. 2005;39(12):2131–5.PubMed
95.
Zurück zum Zitat Taban M, et al. Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm. 2006;14(3):145–50.PubMed Taban M, et al. Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm. 2006;14(3):145–50.PubMed
96.
Zurück zum Zitat Tauber T, et al. Optic neuritis associated with etanercept therapy for juvenile arthritis. J AAPOS. 2006;10(1):26–9.PubMed Tauber T, et al. Optic neuritis associated with etanercept therapy for juvenile arthritis. J AAPOS. 2006;10(1):26–9.PubMed
97.
Zurück zum Zitat Yokoyama W, Takada K, Miyasaka N, Kohsaka H. Myelitis and optic neuritis induced by a long course of etanercept in a patient with rheumatoid arthritis. BMJ Case Rep. 2014 Aug 1; 2014:bcr-2014-205779. Yokoyama W, Takada K, Miyasaka N, Kohsaka H. Myelitis and optic neuritis induced by a long course of etanercept in a patient with rheumatoid arthritis. BMJ Case Rep. 2014 Aug 1; 2014:bcr-2014-205779.
98.
Zurück zum Zitat Mejico LJ. Infliximab-associated retrobulbar optic neuritis. Arch Ophthalmol. 2004;122(5):793–4.PubMed Mejico LJ. Infliximab-associated retrobulbar optic neuritis. Arch Ophthalmol. 2004;122(5):793–4.PubMed
99.
Zurück zum Zitat Teo HMT, de Sá FF, Demirci H. Association of blepharitis and ectropion with tumor necrosis factor α inhibitor treatment in crohn disease. JAMA Ophthalmol. 2019;137(2):232–3.PubMed Teo HMT, de Sá FF, Demirci H. Association of blepharitis and ectropion with tumor necrosis factor α inhibitor treatment in crohn disease. JAMA Ophthalmol. 2019;137(2):232–3.PubMed
100.
Zurück zum Zitat Yoshida M, et al. Endophthalmitis associated with Purpureocillium lilacinum during infliximab treatment for surgically induced necrotizing scleritis, successfully treated with 27-gauge vitrectomy. Int Ophthalmol. 2018;38(2):841–7.PubMed Yoshida M, et al. Endophthalmitis associated with Purpureocillium lilacinum during infliximab treatment for surgically induced necrotizing scleritis, successfully treated with 27-gauge vitrectomy. Int Ophthalmol. 2018;38(2):841–7.PubMed
101.
Zurück zum Zitat Manzano RP, et al. Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit. Graefes Arch Clin Exp Ophthalmol. 2008;246(6):907–11.PubMed Manzano RP, et al. Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit. Graefes Arch Clin Exp Ophthalmol. 2008;246(6):907–11.PubMed
102.
Zurück zum Zitat Becerra CMC, et al. Ocular side effects of antirheumatic medications: a qualitative review. BMJ Open Ophthalmol. 2020;5(1): e000331. Becerra CMC, et al. Ocular side effects of antirheumatic medications: a qualitative review. BMJ Open Ophthalmol. 2020;5(1): e000331.
103.
Zurück zum Zitat Song WK, Cho AR, Yoon YH. Highly suspected primary intraocular lymphoma in a patient with rheumatoid arthritis treated with etanercept: a case report. BMC Ophthalmol. 2018;18(1):156.PubMedPubMedCentral Song WK, Cho AR, Yoon YH. Highly suspected primary intraocular lymphoma in a patient with rheumatoid arthritis treated with etanercept: a case report. BMC Ophthalmol. 2018;18(1):156.PubMedPubMedCentral
104.
Zurück zum Zitat Thomas AS, Rosenbaum JT. Poor control of sarcoidosis-related panuveitis with an antibody to IL-23. Ocul Immunol Inflamm. 2020;28(3):491–3.PubMed Thomas AS, Rosenbaum JT. Poor control of sarcoidosis-related panuveitis with an antibody to IL-23. Ocul Immunol Inflamm. 2020;28(3):491–3.PubMed
105.
Zurück zum Zitat Martinez CE, Allen JB, Davidorf FH, Cebulla CM. Endogenous endophthalmitis and osteomyelitis associated with interleukin 17 inhibitor treatment for psoriasis in a patient with diabetes. BMJ Case Rep. 2017 Jun 29; 2017:bcr2017219296. Martinez CE, Allen JB, Davidorf FH, Cebulla CM. Endogenous endophthalmitis and osteomyelitis associated with interleukin 17 inhibitor treatment for psoriasis in a patient with diabetes. BMJ Case Rep. 2017 Jun 29; 2017:bcr2017219296.
106.
Zurück zum Zitat Javadzadeh S, et al. Ocular toxoplasmosis in a patient treated with ustekinumab for psoriasis. Clin Exp Dermatol. 2020;45(6):802–4.PubMed Javadzadeh S, et al. Ocular toxoplasmosis in a patient treated with ustekinumab for psoriasis. Clin Exp Dermatol. 2020;45(6):802–4.PubMed
107.
Zurück zum Zitat Ruggiero A, et al. Ocular Manifestations in Psoriasis Screening (OcMaPS) Questionnaire: a useful tool to reveal misdiagnosed ocular involvement in psoriasis. J Clin Med. 2021;10(5):1031.PubMedPubMedCentral Ruggiero A, et al. Ocular Manifestations in Psoriasis Screening (OcMaPS) Questionnaire: a useful tool to reveal misdiagnosed ocular involvement in psoriasis. J Clin Med. 2021;10(5):1031.PubMedPubMedCentral
108.
Zurück zum Zitat Grzybowski A, et al. Toxic optic neuropathies: an updated review. Acta Ophthalmol. 2015;93(5):402–10.PubMed Grzybowski A, et al. Toxic optic neuropathies: an updated review. Acta Ophthalmol. 2015;93(5):402–10.PubMed
109.
Zurück zum Zitat Kim A, Saffra N. A case report of adalimumab-associated optic neuritis. J Ophthalmic Inflamm Infect. 2012;2(3):145–7.PubMedPubMedCentral Kim A, Saffra N. A case report of adalimumab-associated optic neuritis. J Ophthalmic Inflamm Infect. 2012;2(3):145–7.PubMedPubMedCentral
110.
Zurück zum Zitat Saffra N, Astafurov K. Visual loss induced by adalimumab used for plaque psoriasis. Case Rep Dermatol. 2017;9(1):60–4.PubMedPubMedCentral Saffra N, Astafurov K. Visual loss induced by adalimumab used for plaque psoriasis. Case Rep Dermatol. 2017;9(1):60–4.PubMedPubMedCentral
111.
Zurück zum Zitat Schechet SA, et al. Acute retinal necrosis after administration of adalimumab, a systemic antitumor necrosis factor antibody. Retin Cases Brief Rep. 2018;12(4):307–9.PubMed Schechet SA, et al. Acute retinal necrosis after administration of adalimumab, a systemic antitumor necrosis factor antibody. Retin Cases Brief Rep. 2018;12(4):307–9.PubMed
112.
Zurück zum Zitat Dermawan A, et al. Infliximab-induced optic neuritis. BMJ Case Rep. 2020;13(12): e236041.PubMed Dermawan A, et al. Infliximab-induced optic neuritis. BMJ Case Rep. 2020;13(12): e236041.PubMed
Metadaten
Titel
Identifying and Treating Ocular Manifestations in Psoriasis
verfasst von
Mahsaw Motlagh
Christopher Fortenbach
Howard I. Maibach
Bobeck S. Modjtahedi
Publikationsdatum
03.11.2021
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 1/2022
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-021-00648-x

Weitere Artikel der Ausgabe 1/2022

American Journal of Clinical Dermatology 1/2022 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.